Aytu Biopharma Overview
- Year Founded
-
2015
- Status
-
Public
- Employees
-
102
- Stock Symbol
-
AYTU
- Investments
-
11
- Share Price
-
$1.44
- (As of Friday Closing)
Aytu Biopharma General Information
Description
Aytu BioPharma Inc is a specialty pharmaceutical company with a commercial portfolio of prescription therapeutics and consumer health products. The company's primary prescription products treat attention deficit hyperactivity disorder and other common pediatric conditions. It is building a complementary therapeutic development pipeline including a prospective treatment (AR101/enzastaurin) for vascular Ehlers-Danlos Syndrome, a rare genetic disease resulting in high morbidity and a significantly shortened lifespan. The company operates in two segments Rx Segment, consisting of prescription pharmaceutical products and Consumer Health segments of which the company generates maximum revenue from the Rx segment.
Contact Information
Website
www.aytubio.comCorporate Office
- Denver Corporate Center III, 7900 East Union Avenue
- Suite 920
- Denver, CO 80237
- United States
Corporate Office
- Denver Corporate Center III, 7900 East Union Avenue
- Suite 920
- Denver, CO 80237
- United States
Aytu Biopharma Stock Performance
As of 13-Dec-2024, Aytu Biopharma’s stock price is $1.44. Its current market cap is $8.86M with 6.15M shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $1.44 | $1.50 | $1.40 - $3.45 | $8.86M | 6.15M | 35.8K | -$1.14 |
Aytu Biopharma Financials Summary
As of 30-Sep-2024, Aytu Biopharma has a trailing 12-month revenue of $75.5M.
|
In Thousands, USD |
TTM 30-Sep-2024 | FY 2024 30-Jun-2024 | FY 2023 30-Jun-2023 | FY 2022 30-Jun-2022 |
|---|---|---|---|---|
| EV | 9,573 | 14,395 | 14,753 | 20,265 |
| Revenue | 75,477 | 81,002 | 107,399 | 96,669 |
| EBITDA | 2,250 | (1,884) | (4,688) | (99,089) |
| Net Income | (6,250) | (15,844) | (17,051) | (108,779) |
| Total Assets | 115,831 | 118,095 | 136,463 | 137,623 |
| Total Debt | 16,557 | 15,129 | 16,361 | 18,188 |
Aytu Biopharma Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Aytu Biopharma Comparisons
Industry
Financing
Details
Aytu Biopharma Competitors (7)
One of Aytu Biopharma’s 7 competitors is Antares Pharma, a Formerly VC-backed company based in Ewing, NJ.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Antares Pharma | Formerly VC-backed | Ewing, NJ | ||||
| Novartis | Corporation | Basel, Switzerland | ||||
| Tris Pharma | Private Debt Financed | Monmouth Junction, NJ | ||||
| Takeda Pharmaceutical Company | Corporation | Tokyo, Japan | ||||
| Urigen N.A. | Corporate Backed or Acquired | North Brunswick, NJ |
Aytu Biopharma Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Aytu Biopharma Patents
Aytu Biopharma Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-11534474-B1 | Oral compositions for bladder regulation and uses thereof | Active | 29-Jul-2021 | ||
| CA-3171318-A1 | Oral compositions for bladder regulation and uses thereof | Pending | 29-Jul-2021 | ||
| US-20160313296-A1 | Use of orp for characterizing stroke patients | Inactive | 21-Apr-2015 | ||
| EP-3223747-A2 | Determination of fertility potential from the oxidation-reduction potential of a biological sample | Active | 25-Nov-2014 | ||
| AU-2015353639-B2 | Determination of fertility potential from the oxidation-reduction potential of a biological sample | Inactive | 25-Nov-2014 | G01N33/48707 |
Aytu Biopharma Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Aytu Biopharma Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Aytu Biopharma Investments & Acquisitions (11)
Aytu Biopharma’s most recent deal was a Merger/Acquisition with Rumpus Therapeutics for . The deal was made on 12-Apr-2021.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Rumpus Therapeutics | 12-Apr-2021 | Merger/Acquisition | Drug Discovery | ||
| Neos Therapeutics | 19-Mar-2021 | Merger/Acquisition | Drug Discovery | ||
| Innovus Pharmaceuticals | 14-Feb-2020 | Merger/Acquisition | Pharmaceuticals | ||
| Cerecor (Pediatric Portfolio) | 01-Nov-2019 | Corporate Asset Purchase | Buildings and Property | ||
| Tris Pharma (Tuzistra XR) | 02-Nov-2018 | Corporate Asset Purchase | Buildings and Property |
Aytu Biopharma Subsidiaries (1)
| Company Name | Industry | Location | Founded |
|---|---|---|---|
| Innovus Pharmaceuticals | Pharmaceuticals | San Diego, CA |
Aytu Biopharma ESG
Risk Overview
Risk Rating
Updated August, 31, 2020
15.3 | Low Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 14,042
Rank
Percentile
Consumer Services
Industry
of 434
Rank
Percentile
Consumer Services
Subindustry
of 120
Rank
Percentile
Aytu Biopharma Exits (1)
Aytu Biopharma’s most recent exit was on 31-Oct-2015 from FSC Pediatrics (Primsol Business). The exit was categorized as .
| Company Name | Exit Date | Exit Type | Exit Size | Status | Buyers |
|---|---|---|---|---|---|
| FSC Pediatrics (Primsol Business) | 31-Oct-2015 | Completed |
|
Aytu Biopharma FAQs
-
When was Aytu Biopharma founded?
Aytu Biopharma was founded in 2015.
-
Where is Aytu Biopharma headquartered?
Aytu Biopharma is headquartered in Denver, CO.
-
What is the size of Aytu Biopharma?
Aytu Biopharma has 102 total employees.
-
What industry is Aytu Biopharma in?
Aytu Biopharma’s primary industry is Biotechnology.
-
Is Aytu Biopharma a private or public company?
Aytu Biopharma is a Public company.
-
What is Aytu Biopharma’s stock symbol?
The ticker symbol for Aytu Biopharma is AYTU.
-
What is the current stock price of Aytu Biopharma?
As of 13-Dec-2024 the stock price of Aytu Biopharma is $1.44.
-
What is the current market cap of Aytu Biopharma?
The current market capitalization of Aytu Biopharma is $8.86M.
-
What is Aytu Biopharma’s current revenue?
The trailing twelve month revenue for Aytu Biopharma is $75.5M.
-
Who are Aytu Biopharma’s competitors?
Antares Pharma, Novartis, Tris Pharma, Takeda Pharmaceutical Company, and Urigen N.A. are some of the 7 competitors of Aytu Biopharma.
-
What is Aytu Biopharma’s annual earnings per share (EPS)?
Aytu Biopharma’s EPS for 12 months was -$1.14.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
